论文部分内容阅读
68例FPG≥13mmol/L的新诊T2DM患者随机分为Glarlgine组,n=35和NPH组,n=33,两组均采用1天4次胰岛素皮下注射。结果2周后,①两组血糖(PG)、糖化血红蛋白(HbA1c)均显著降低,但(P>0.05);②血糖控制相近的情况下,Glarlgine组Glarlgine用量≈NPH组诺和灵N剂量×140%,但每日胰岛素(Ins)总量显著减少(P<0.05);③与NPH组相比,Glarlgine组日间血糖波动更小(P<0.05),低血糖发生率更低(P<0.05)。结论治疗相同的患者,Glarlgine用量≈诺和灵N剂量×140%,且血糖波动更小、低血糖发生率更低,更安全。
Sixty-eight newly diagnosed T2DM patients with FPG≥13mmol / L were randomly divided into Glarlgine group, n = 35 and NPH group, n = 33, and subcutaneous injection of insulin 4 times a day was used in both groups. Results After two weeks, the levels of Glarlgine and Noradrenaline N in Glarlgine group were significantly lower than those in Glarlgine group (P> 0.05) (P <0.05). Compared with NPH group, Glarlgine had less fluctuation of daytime blood glucose (P <0.05) and lower incidence of hypoglycemia (P < 0.05). Conclusion In the same treatment group, the dose of Glarlgine ≈Noledrine N × 140%, with less fluctuation of blood glucose, lower incidence of hypoglycemia and safer.